Gastrointestinal (GI): NSAIDs that block COX-1 activity have correlations with GI complications because of the inhibition with the synthesis of gastroprotective brokers like PGE2 and other prostaglandins. This inhibition results in reduced mucin production by gastric epithelial cells, considerably less bicarbonate secretion, and fewer epithelial mobile turnover, among the other https://richardh741uwv5.rimmablog.com/profile